{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:59:54Z","timestamp":1762480794755,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T00:00:00Z","timestamp":1548547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.gore.2019.01.010","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:56:59Z","timestamp":1549004219000},"page":"18-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast\/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers"],"prefix":"10.1016","volume":"28","author":[{"given":"Martha E.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne T.","family":"Knisely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie W.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari L.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan C.","family":"Modesitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.gore.2019.01.010_bb0005","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.gore.2019.01.010_bb0010","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/AOG.0000000000002916","article-title":"Hereditary cancer risk assessment and genetic testing in the community-practice setting","volume":"132","author":"DeFrancesco","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"15","key":"10.1016\/j.gore.2019.01.010_bb0015","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2019.01.010_bb0020","doi-asserted-by":"crossref","first-page":"425.e1","DOI":"10.1016\/j.ajog.2017.06.004","article-title":"Persistence of fimbrial tissue on the ovarian surface after salpingectomy","volume":"217","author":"Gan","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.gore.2019.01.010_bb0025","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gore.2019.01.010_bb0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.gore.2019.01.010_bb0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/157340409787721294","article-title":"Long-term survival and cost of treatment in patients with stage IIIC epithelial ovarian cancer","volume":"5","author":"Louis","year":"2009","journal-title":"Curr. Women's Health Rev."},{"key":"10.1016\/j.gore.2019.01.010_bb0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2011.10.017","article-title":"The role of peritoneal cytology at risk-reducing salpingo-oophorectomy in women at increased risk of familial ovarian\/tubal cancer","volume":"124","author":"Manchanda","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2019.01.010_bb0045","series-title":"ACOG Practice Bulletin","first-page":"e110","article-title":"Hereditary breast and ovarian cancer syndrome","volume":"182","author":"Modesitt","year":"2017"},{"year":"2018","series-title":"Genetic\/Familial High-Risk Assessment: Breast and Ovarian","author":"National Comprehensive Cancer Network","key":"10.1016\/j.gore.2019.01.010_bb0050"},{"issue":"3","key":"10.1016\/j.gore.2019.01.010_bb0055","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.gore.2019.01.010_bb0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/0008-5472.CAN-15-1382","article-title":"It's totally tubular\u2026riding the new wave of ovarian cancer research","volume":"76","author":"Perets","year":"2016","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.gore.2019.01.010_bb0065","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2019.01.010_bb0070","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.gore.2019.01.010_bb0075","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578919300104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578919300104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:55:03Z","timestamp":1762480503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578919300104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":15,"alternative-id":["S2352578919300104"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2019.01.010","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast\/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2019.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}